Rocket Pharmaceuticals, Inc.
RCKT
$4.87
$0.142.96%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.68M | 18.35M | 25.02M | 28.45M | 25.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.03M | 52.42M | 67.68M | 64.39M | 62.69M |
| Operating Income | -44.03M | -52.42M | -67.68M | -64.39M | -62.69M |
| Income Before Tax | -42.54M | -50.33M | -68.92M | -61.33M | -60.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.54M | -50.33M | -68.92M | -61.33M | -60.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.54M | -50.33M | -68.92M | -61.33M | -60.33M |
| EBIT | -44.03M | -52.42M | -67.68M | -64.39M | -62.69M |
| EBITDA | -41.81M | -49.18M | -65.10M | -61.40M | -60.33M |
| EPS Basic | -0.38 | -0.45 | -0.62 | -0.56 | -0.62 |
| Normalized Basic EPS | -0.25 | -0.29 | -0.38 | -0.36 | -0.39 |
| EPS Diluted | -0.38 | -0.45 | -0.62 | -0.56 | -0.62 |
| Normalized Diluted EPS | -0.25 | -0.29 | -0.38 | -0.36 | -0.39 |
| Average Basic Shares Outstanding | 111.79M | 111.57M | 111.02M | 110.09M | 97.53M |
| Average Diluted Shares Outstanding | 111.79M | 111.57M | 111.02M | 110.09M | 97.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |